Stock Price Quote

ADVANCED ENZYME TECHNOLOGIES LTD.

NSE : ADVENZYMESBSE : 540025ISIN CODE : INE837H01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE296.45-4 (-1.33 %)
PREV CLOSE ( ) 300.45
OPEN PRICE ( ) 297.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3810
TODAY'S LOW / HIGH ( )293.90 300.90
52 WK LOW / HIGH ( )257.85 366.55
NSE296.95-4 (-1.33 %)
PREV CLOSE( ) 300.95
OPEN PRICE ( ) 298.30
BID PRICE (QTY) 296.95 (176)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 53808
TODAY'S LOW / HIGH( ) 293.40 303.20
52 WK LOW / HIGH ( )257.9 366.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-03 1989
Management Info
Vasant Rathi - Chairman - Managing Director
Registered Office

Address Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,Louiswadi,
Thane,
Maharashtra-400604

Phone 022 41703200

Email info@advancedenzymes.com

Website www.advancedenzymes.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

15Jan Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that the Statutory Auditors of..
26Dec Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that the ‘Trading Window’ for..
07Oct Advanced Enzyme Technologies informs
Advanced Enzyme Technologies has informed that the Security Allotment Co..
12Mar Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that pursuant to the Securitie..
19Dec Advanced Enzyme Technologies completes
Advanced Enzyme Technologies has completed the further investment in Adv..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit132.481024.2
Gross Profit 178.16 1205.28
Operating Profit 247.561321.69
Net Sales 955.843514.11

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  13242.00 (1.52%)
M.Cap ( in Cr)16989.34
Torrent Pharma (BSE)
peergroup  4260.45 (4.58%)
M.Cap ( in Cr)144192.99
Procter&Gamble Healt (BSE)
peergroup  5061.35 (1.72%)
M.Cap ( in Cr)8401.53
JB Chem & Pharma (BSE)
peergroup  1977.85 (4.50%)
M.Cap ( in Cr)31749.94
Alkem Laboratories (BSE)
peergroup  5480.30 (1.46%)
M.Cap ( in Cr)65525.21

Shareholding Pattern

PROMOTERS 43.04%
NON-INSTITUTION 25.6%
MUTUAL FUNDS/UTI 2.16%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Advanced Enzyme Technologies Ltd.

Advanced Enzyme Technologies Ltd. was incorporated in the year 1989. Its today's share price is 296.45. Its current market capitalisation stands at Rs 3318.07 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3514.11 Cr and Total Income of Rs.4129.01 Cr. The company's management includes Vandana Tilak, Nitin Deshmukh, Rajshree Patel, Sunny Sharma, Vinodkumar Jajoo, Pramod Kasat, Rasika Rathi, Mukund Kabra, Vasant Rathi, Sanjay Basantani.

It is listed on the BSE with a BSE Code of 540025 , NSE with an NSE Symbol of ADVENZYMES and ISIN of INE837H01020. It's Registered office is at Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,LouiswadiThane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, MM Nissim & Co, MSKA & Associates, Walker Chandiok & Co LLP, Walker, Chandiok & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.